TG THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
TG THERAPEUTICS, INC. (TGTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $441.00K, a 2.08% increase year-over-year.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $573.00K, a 26.49% increase year-over-year.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $432.00K, a 13.25% decline year-over-year.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $431.00K, a 13.28% decline year-over-year.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.75M, a 8.00% decline from fiscal 2024.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.90M, a 3.21% decline from fiscal 2023.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.96M, a 27.70% decline from fiscal 2022.
- TG THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.71M, a 43.20% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.01M 10-Q · filed 2026-08-05 | $1.45M derived: sum of 3 quarters · filed 2026-08-05 | $1.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $573.00K 10-Q · filed 2026-05-06 | $1.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.44M derived: sum of 3 quarters · filed 2026-05-06 | $1.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $863.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.29M derived: sum of 3 quarters · filed 2026-08-05 | $1.75M 10-K · filed 2026-02-27 |
| 2025-09-30 | $431.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $863.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.32M 10-Q · filed 2025-11-05 | $1.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $885.00K 10-Q · filed 2026-08-05 | $1.38M derived: sum of 3 quarters · filed 2026-08-05 | $1.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $453.00K 10-Q · filed 2026-05-06 | $951.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.45M derived: sum of 3 quarters · filed 2026-05-06 | $1.95M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $995.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.49M derived: sum of 3 quarters · filed 2026-02-27 | $1.90M 10-K · filed 2026-02-27 |
| 2024-09-30 | $497.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $995.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.40M 10-Q · filed 2025-11-05 | $1.89M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $905.00K 10-Q · filed 2025-08-08 | $1.40M derived: sum of 3 quarters · filed 2026-02-27 | $1.88M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $407.00K 10-Q · filed 2025-05-09 | $897.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.38M derived: sum of 3 quarters · filed 2026-02-27 | $1.88M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $973.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.47M derived: sum of 3 quarters · filed 2026-02-27 | $1.96M 10-K · filed 2026-02-27 |
| 2023-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $982.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.47M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $990.00K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $491.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $2.71M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $1.90M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |